Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 104 publications
Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer.
Journal: CPT: pharmacometrics & systems pharmacology
Published: March 27, 2026
Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 23, 2026
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 01, 2025
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
Journal: The New England journal of medicine
Published: September 09, 2025
Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib.
Journal: Clinical lung cancer
Published: August 19, 2025
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 17, 2025
JNJ-79032421, a Novel Membrane-restricted Mesothelin-targeting T-cell-engaging Bispecific Antibody for the Treatment of Mesothelin-positive Cancers.
Journal: Molecular cancer therapeutics
Published: June 16, 2025
Plain language summary of first-line amivantamab-lazertinib in previously untreated high-risk EGFR-altered non-small-cell lung cancer in MARIPOSA.
Journal: Future oncology (London, England)
Published: April 24, 2025
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 06, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 28, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 10, 2025
Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 21, 2025
Last Updated: 09/26/2026